Cost of Revenue Comparison: Teva Pharmaceutical Industries Limited vs Galapagos NV

Teva vs. Galapagos: A Decade of Cost Dynamics

__timestampGalapagos NVTeva Pharmaceutical Industries Limited
Wednesday, January 1, 20141111100009216000000
Thursday, January 1, 20151297140008296000000
Friday, January 1, 201613957400010044000000
Sunday, January 1, 201721850200011560000000
Monday, January 1, 201832287600010558000000
Tuesday, January 1, 20194273200009351000000
Wednesday, January 1, 20205236670008933000000
Friday, January 1, 202116290008284000000
Saturday, January 1, 2022120790007952000000
Sunday, January 1, 2023359890008200000000
Monday, January 1, 20248480000000
Loading chart...

In pursuit of knowledge

Cost of Revenue: A Tale of Two Pharmaceutical Giants

In the ever-evolving pharmaceutical industry, cost management is crucial for sustaining growth and innovation. This analysis compares the cost of revenue for Teva Pharmaceutical Industries Limited and Galapagos NV from 2014 to 2023. Over this period, Teva's cost of revenue consistently dwarfed that of Galapagos, averaging around 9.2 billion annually, while Galapagos averaged a modest 192 million.

A Decade of Financial Dynamics

Teva's cost of revenue peaked in 2017 at approximately 11.6 billion, reflecting its expansive operations and market reach. In contrast, Galapagos saw its highest cost in 2020, with a 523% increase from 2014, highlighting its growth trajectory. However, the data also reveals a significant drop in Galapagos' costs in 2021, indicating potential strategic shifts or operational efficiencies.

This comparison underscores the diverse financial strategies within the pharmaceutical sector, offering insights into how companies navigate market challenges.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025